Immunome (IMNM) Competitors $7.40 +0.05 (+0.68%) Closing price 04:00 PM EasternExtended Trading$7.25 -0.15 (-2.03%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNM vs. MIRM, VCEL, BHC, BHVN, TARS, GMTX, AAPG, BLTE, NAMS, and MTSRShould you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Mirum Pharmaceuticals (MIRM), Vericel (VCEL), Bausch Health Companies (BHC), Biohaven (BHVN), Tarsus Pharmaceuticals (TARS), Gemini Therapeutics (GMTX), Ascentage Pharma Group International (AAPG), Belite Bio (BLTE), NewAmsterdam Pharma (NAMS), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Immunome vs. Mirum Pharmaceuticals Vericel Bausch Health Companies Biohaven Tarsus Pharmaceuticals Gemini Therapeutics Ascentage Pharma Group International Belite Bio NewAmsterdam Pharma Metsera Immunome (NASDAQ:IMNM) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Does the media prefer IMNM or MIRM? In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Mirum Pharmaceuticals and 4 mentions for Immunome. Mirum Pharmaceuticals' average media sentiment score of 1.37 beat Immunome's score of 0.72 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Mirum Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in IMNM or MIRM? 44.6% of Immunome shares are held by institutional investors. 8.6% of Immunome shares are held by insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, IMNM or MIRM? Immunome has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500. Do analysts rate IMNM or MIRM? Immunome currently has a consensus price target of $25.14, indicating a potential upside of 239.77%. Mirum Pharmaceuticals has a consensus price target of $58.20, indicating a potential upside of 50.66%. Given Immunome's higher probable upside, research analysts clearly believe Immunome is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has higher valuation & earnings, IMNM or MIRM? Immunome has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$9.04M71.17-$106.81M-$5.17-1.43Mirum Pharmaceuticals$336.89M5.62-$163.41M-$1.85-20.88 Does the MarketBeat Community believe in IMNM or MIRM? Mirum Pharmaceuticals received 94 more outperform votes than Immunome when rated by MarketBeat users. However, 77.55% of users gave Immunome an outperform vote while only 75.86% of users gave Mirum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformImmunomeOutperform Votes3877.55% Underperform Votes1122.45% Mirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% Is IMNM or MIRM more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to Immunome's net margin of -3,014.59%. Mirum Pharmaceuticals' return on equity of -41.22% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-3,014.59% -48.63% -41.62% Mirum Pharmaceuticals -31.69%-41.22%-14.81% SummaryMirum Pharmaceuticals beats Immunome on 12 of the 19 factors compared between the two stocks. Remove Ads Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNM vs. The Competition Export to ExcelMetricImmunomePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$643.44M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-0.916.7921.7317.81Price / Sales71.17225.93379.1494.58Price / CashN/A65.6738.1534.64Price / Book2.675.866.464.00Net Income-$106.81M$141.86M$3.20B$247.23M7 Day Performance33.09%8.98%6.54%7.26%1 Month Performance-15.62%-12.65%-8.55%-6.26%1 Year Performance-60.74%-11.99%10.33%-0.18% Immunome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNMImmunome2.3802 of 5 stars$7.40+0.7%$25.14+239.8%-64.3%$643.44M$9.04M-0.9140MIRMMirum Pharmaceuticals3.9743 of 5 stars$41.00-2.5%$58.20+42.0%+61.1%$2.01B$336.89M-20.30140Positive NewsVCELVericel2.4154 of 5 stars$39.90-4.8%$62.29+56.1%-13.9%$2.00B$237.22M665.11300News CoverageHigh Trading VolumeBHCBausch Health Companies4.0037 of 5 stars$5.26-1.4%$7.17+36.4%-50.6%$1.93B$9.63B-43.7919,900Short Interest ↑BHVNBiohaven3.5018 of 5 stars$17.86-3.9%$62.77+251.4%-65.2%$1.82BN/A-1.91239TARSTarsus Pharmaceuticals2.9463 of 5 stars$47.49+1.0%$63.67+34.1%+34.7%$1.82B$182.95M-12.4650Positive NewsGMTXGemini TherapeuticsN/A$41.22-9.9%N/A+21.7%$1.79BN/A-41.2230Gap UpHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$20.40-2.6%N/AN/A$1.78B$980.65M0.00600Positive NewsGap DownBLTEBelite Bio2.8619 of 5 stars$55.67-2.2%$96.67+73.6%+58.8%$1.77BN/A-50.1510Short Interest ↓NAMSNewAmsterdam Pharma2.2865 of 5 stars$15.86+0.3%$43.33+173.2%-16.6%$1.74B$45.56M-6.104Short Interest ↑High Trading VolumeMTSRMetseraN/A$16.45-2.1%$47.00+185.7%N/A$1.73BN/A0.0081High Trading Volume Remove Ads Related Companies and Tools Related Companies MIRM Competitors VCEL Competitors BHC Competitors BHVN Competitors TARS Competitors GMTX Competitors AAPG Competitors BLTE Competitors NAMS Competitors MTSR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNM) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMNM Stock Free IMNM Stock Alerts